Oncology Institute (NASDAQ:TOI) Shares Up 1.3%

The Oncology Institute, Inc. (NASDAQ:TOIGet Rating)’s share price shot up 1.3% during mid-day trading on Wednesday . The stock traded as high as $0.48 and last traded at $0.43. 468,333 shares were traded during trading, an increase of 187% from the average session volume of 163,166 shares. The stock had previously closed at $0.42.

Wall Street Analysts Forecast Growth

Separately, Guggenheim lowered their price target on shares of Oncology Institute from $6.00 to $3.00 in a report on Monday, March 20th.

Oncology Institute Trading Down 3.7 %

The company has a current ratio of 3.95, a quick ratio of 3.61 and a debt-to-equity ratio of 0.83. The firm has a fifty day moving average of $0.57 and a 200 day moving average of $1.18.

Oncology Institute (NASDAQ:TOIGet Rating) last posted its quarterly earnings data on Thursday, March 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. Oncology Institute had a negative return on equity of 26.61% and a negative net margin of 17.41%. The company had revenue of $71.42 million for the quarter, compared to the consensus estimate of $65.46 million. On average, equities analysts forecast that The Oncology Institute, Inc. will post -0.63 earnings per share for the current year.

Insider Activity

In related news, Director Richard A. Barasch acquired 50,000 shares of Oncology Institute stock in a transaction that occurred on Friday, March 17th. The stock was acquired at an average price of $0.55 per share, for a total transaction of $27,500.00. Following the transaction, the director now directly owns 257,193 shares of the company’s stock, valued at approximately $141,456.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in shares of Oncology Institute by 101.8% during the third quarter. BlackRock Inc. now owns 1,529,650 shares of the company’s stock worth $7,083,000 after purchasing an additional 771,555 shares during the period. Vanguard Group Inc. increased its position in Oncology Institute by 89.5% in the 1st quarter. Vanguard Group Inc. now owns 838,321 shares of the company’s stock worth $5,977,000 after purchasing an additional 395,977 shares during the last quarter. Triatomic Management LP increased its position in Oncology Institute by 56.6% in the 1st quarter. Triatomic Management LP now owns 810,145 shares of the company’s stock worth $549,000 after purchasing an additional 292,666 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Oncology Institute in the 4th quarter worth about $318,000. Finally, State Street Corp increased its position in Oncology Institute by 538.7% in the 2nd quarter. State Street Corp now owns 198,627 shares of the company’s stock worth $1,005,000 after purchasing an additional 167,527 shares during the last quarter. Institutional investors and hedge funds own 70.45% of the company’s stock.

About Oncology Institute

(Get Rating)

The Oncology Institute, Inc, an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.

Featured Articles

Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.